FTSE MIB
34.694,43 +202,02 (+0,59%) Dow Jones
38.686,32 +574,82 (+1,51%) Nasdaq
16.735,02 -2,08 (-0,01%) Nikkei 225
38.923,03 +435,13 (+1,13%) Petrolio
76,87 -0,12 (-0,16%) Bitcoin EUR
63.689,31 +1.402,08 (+2,25%)
CRBP Dec 2024 25.000 put
| Chiusura precedente | 4,7000 |
| Aperto | 4,7000 |
| Denaro | 0,0000 |
| Domanda | 0,0000 |
| Prezzo d'esercizio | 25,00 |
| Scadenza | 2024-12-20 |
| Min-Max giorno | 4,7000 - 4,7000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | N/D |
GlobeNewswireCorbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701
CRB-701 demonstrates a differentiated nonclinical profile relative to enfortumab vedotinEarly dose escalation clinical data supports differentiating features established pre-clinicallyThe company on schedule to initiate its US study in Q1-2024 NORWOOD, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that a poster characterizing the pre-clinical validation of CRB-701, a next ge
- GlobeNewswire
Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
NORWOOD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the development of a next generation Nectin-4 antibody drug conjugate, focusing on opportunities and challenges for CRB-701, on Tuesday, October 10, 2023 at 10:30am ET. To register for the webinar, click here. The event will feature several Oncology experts Daniel P.
